Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML

Z. Y. Lim, W. Ingram, R. Brand, A. Ho, M. Kenyon, S. Devereux, J. Marsh, G. J. Mufti, A. Pagliuca

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML'. Together they form a unique fingerprint.